
Ipca Laboratories Ltd. share price
NSE: IPCALAB · Healthcare
₹1,865.50 -0.98%
Closing price data, updated 17 Nov 2026. 52-week range: -8.5% from high, +44.2% above low.
Price₹1,865.50
Market cap₹47,329 Cr
P/E33.8
P/B5.45
ROE15.2%
ROCE16.4%
Debt / equity0.10
Dividend yield0.00%
EPS₹55.28
Book value₹342.06
Operating margin17.1%
Dipscan score67 / 100
Share: WhatsAppX / TwitterTelegram
Ipca Laboratories Ltd. shareholding pattern
As of Sep 2026: Promoters 44.72%, FIIs 11.53%, DIIs 36.59%, Government 0.00%, Public 5.72%, Others 1.43%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% |
| FIIs | 11.53% | 10.73% | 10.63% | 10.63% | 10.43% | 10.67% |
| DIIs | 36.59% | 37.37% | 37.45% | 37.32% | 36.77% | 36.20% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 5.72% | 5.76% | 5.79% | 5.88% | 6.55% | 6.82% |
| Others | 1.43% | 1.42% | 1.41% | 1.44% | 1.53% | 1.59% |
| No. of Shareholders | 90,514 | 82,060 | 82,184 | 77,673 | 82,870 | 85,582 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| -0.98% | -3.93% | -2.41% | +3.85% | +17.78% | +38.72% |
Growth
| Sales growth, 3 years | +15.5% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +34.3% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | +13.8% |
| Latest quarter profit vs last year | +32.8% |
Strengths and weaknesses
Strengths
- Company has reduced debt.
- Company is almost debt free.
Weaknesses
- Stock is trading at 5.45 times its book value
- Company has a low return on equity of 12.9% over last 3 years.
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Ipca Laboratories Ltd.?
Ipca Laboratories Ltd. (IPCALAB) last closed at ₹1,865.50 (-0.98% on the day).
What is the market cap of Ipca Laboratories Ltd.?
About ₹47,329 Cr.
What is the P/E ratio of Ipca Laboratories Ltd.?
The price-to-earnings ratio is 33.8, and return on equity is 15.2%.
Figures are calculated from company results and exchange prices and are for information only.